The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC

被引：3
|
作者：
Elamin, Y. [1 ]
Robichaux, J. [1 ]
Lam, V. [2 ]
Tsao, A. [3 ]
Lu, C. [1 ]
Blumenschein, G. [4 ]
Kurie, J. [1 ]
Brahmer, J. [5 ]
Li, S.
Chen, T. [7 ]
Estrada-Bernal, A. [8 ]
Truini, A. [9 ]
Nilsson, M. [1 ]
Le, A.
Tan, Z. [1 ]
Zhang, S. [1 ]
Doebele, R. [10 ]
Politi, K. [9 ,12 ]
Yang, Z. [11 ]
Liu, S. [6 ]
Wong, K.
Heymach, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Thorac & Head & Neck Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Univ Colorado Amc, Med Oncol, Aurora, CO USA
[9] Yale Univ, Pathol, New Haven, CT USA
[10] Univ Colorado, Div Med Oncol, Aurora, CO USA
[11] Spectrum Pharmaceut, Irvine, CA USA
[12] NYU, Langone Med Ctr, Div Hematol Oncol, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR Exon 20 Insertion mutation; Novel targeted therapy;
D O I：
10.1016/j.jtho.2017.09.394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 12.01
引用
收藏
页码：S1776 / S1776
页数：1
相关论文
共 50 条
  • [1] Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions.
    Siegel, Franziska
    Siegel, Stephan
    Graham, Keith
    Kaplan, Bethany
    Petersen, Kirstin
    Boemer, Ulf
    Eberspaecher, Uwe
    Korr, Daniel
    Moenning, Ursula
    Suelzle, Detlev
    Schroeder, Jens
    Prinz, Florian
    Zitzmann-Kolbe, Sabine
    Karsli-Uzunbas, Gizem
    Lewis, Timothy
    Hermsen, Mario
    Cherniack, Andrew
    von Nussbaum, Franz
    Eis, Knut
    Meyerson, Matthew
    Greulich, Heidi
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [2] Preliminary Results of a Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
    Elamin, Y.
    Robichaux, J.
    Heymach, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) : S1536 - S1536
  • [3] Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions
    Floc'h, Nicolas
    Martin, Matthew J.
    Riess, Jonathan W.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Menard, Ludovic
    Cuomo, Maria Emanuela
    O'Neill, Daniel J.
    Ward, Richard A.
    Finlay, M. Raymond V.
    McKerrecher, Darren
    Cheng, Mingshan
    Vang, Daniel P.
    Burich, Rebekah A.
    Keck, James G.
    Gandara, David R.
    Mack, Philip C.
    Cross, Darren A. E.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 885 - 896
  • [4] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
    Elamin, Yasir Y.
    Robichaux, Jacqulyne P.
    Carter, Brett W.
    Altan, Mehmet
    Tran, Hai
    Gibbons, Don L.
    Heeke, Simon
    Fossella, Frank, V
    Lam, Vincent K.
    Le, Xiuning
    Negrao, Marcelo, V
    Nilsson, Monique B.
    Patel, Anisha
    Vijayan, R. S. K.
    Cross, Jason B.
    Zhang, Jianjun
    Byers, Lauren A.
    Lu, Charles
    Cascone, Tina
    Feng, Lei
    Luthra, Rajyalakshmi
    San Lucas, Francis A.
    Mantha, Geeta
    Routbort, Mark
    Blumenschein, George, Jr.
    Tsao, Anne S.
    Heymach, John, V
    [J]. CANCER CELL, 2022, 40 (07) : 754 - +
  • [5] Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR
    Floc'h, Nicolas
    Ashton, Susan
    Bianco, Ambra
    Colclough, Nicola
    Cross, Darren A. E.
    Cuomo, Maria Emanuela
    Finlay, M. Raymond V.
    Martin, Matthew J.
    Menard, Ludovic
    McKerrecher, Darren
    O'Neill, Daniel J.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Ward, Richard A.
    Yates, James W. T.
    [J]. CANCER RESEARCH, 2017, 77
  • [6] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [7] CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.
    Le, Xiuning
    Garassino, Marina Chiara
    Cornelissen, Robin
    Socinski, Mark A.
    Tchekmedyian, Nishan
    Molina, Julian R.
    Baik, Christina S.
    Leu, Sharon
    Dreiling, Lyndah
    Lebel, Francois M.
    Clarke, Jeffrey Melson
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study
    Le, Xiuning
    Goldman, Jonathan
    Clarke, Jeffrey
    Techekmedyian, Nishan
    Piotrowska, Zofia
    Chu, David
    Bhat, Gajanan
    Lebel, Francois
    Socinski, Mark
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [9] Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
    Le, Xiuning
    Goldman, Jonathan Wade
    Clarke, Jeffrey Melson
    Tchekmedyian, Nishan
    Piotrowska, Zofia
    Chu, David
    Bhat, Gajanan
    Lebel, Francois M.
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] TPC-064, a novel mutant-selective EGFR inhibitor, targets NSCLC driven by EGFR exon 20 insertion mutations
    Hasako, S.
    Terasaka, M.
    Ito, S.
    Kato, M.
    Aoyagi, Y.
    Uno, T.
    Matsuo, K.
    Utsugi, T.
    Iwasawa, Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S125 - S126
12345